J&J In-Licenses Cancer-Related Muscle Loss Agent Andarine From GTx
This article was originally published in The Pink Sheet Daily
Executive Summary
Ortho Biotech deal allows GTx to co-promote andarine to urologists using its own specialty sales force. The force would also market Acapodene for the treatment of side effects associated with prostate cancer therapy.